RHHBY•benzinga•
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Summary
Roche's MUSETTE trial found no additional benefit of high-dose Ocrevus over the 600 mg IV dose, reaffirming its efficacy and safety for relapsing multiple sclerosis.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 2, 2025 by benzinga